Glucagon-like peptide-2-loaded microspheres as treatment for ulcerative colitis in the murine model

References

• Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M, Gomariz RP. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn’s disease. Gastroenterology, 2003;124:961–71
   PubMed Web of Science ®Google Scholar
• Abad C, Juarranz Y, Martinez C, Arranz A, Rosignoli F, García-Gómez M, Leceta J, Gomariz RP. cDNA array analysis of cytokines, chemokines and receptors involved in the development of TNBS-induced colitis; homeostatic role of VIP. Inflamm Bowel Dis, 2005;11:674–84
   PubMed Web of Science ®Google Scholar
• Alters SE, McLaughlin B, Spink B, Lachinyan T, Wang CW, Podust V, Schellenberger V, Stemmer WP. GLP2-2G-XTEN: A pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's. PLoS One, 2012;7(11):e50630
   PubMed Web of Science ®Google Scholar
• Araki Y, Mukaisyo K, Sugihara H, Fujiyama Y, Hattori T. Increased apoptosis and decreased proliferation of colonic epithelium in dextran sulfte sodium-induced colitis in mice. Oncology Rep, 2010;24(4):869–74
   PubMed Web of Science ®Google Scholar
• Arthur GL, Schwartz MZ, Kuenzler KA, Birbe R. Glucagonlike peptide-2 analogue: A possible new approach in the management of inflammatory bowel disease. J Pediatr Surg, 2004;39:448–52
   PubMed Web of Science ®Google Scholar
• Bao W, Zhou JX, Luo JF, Wu DX. PLGA microspheres with high drug loading and high encapsulation efficiency prepared by a novel solvent evaporation technique. J Microencapsul, 2006;23(5):471–9
   PubMed Web of Science ®Google Scholar
• Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut, 2000;47(1):112–19
   PubMed Web of Science ®Google Scholar
• Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol Endocrinol Metab, 1999;277:E937–47
   Web of Science ®Google Scholar
• Brubaker PL, Izzo A, Hill M, Drucker DJ. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol Endocr Metab, 1997;272:1050–8
   PubMed Web of Science ®Google Scholar
• Buchman AL1, Katz S, Fang JC, Bernstein CN, Abou-Assi SG. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn’s disease. Inflamm Bowel Dis, 2010;16:962–73
   PubMed Web of Science ®Google Scholar
• Cameron HL, Perdue MH. Stress impairs murine intestinal barrier function: Improvement by glucagon-like peptide-2. J Pharmacol Exp Ther, 2005;314:214–20
   PubMed Web of Science ®Google Scholar
• Chance WT, Sheriff S, McCarter F, Ogle C. Glucagon-like peptide-2 stimulates gut mucosal growth and immune response in burned rats. J Burn Care Rehabil, 2001;22:136–43
   PubMedGoogle Scholar
• Chung CY, Park YL, Kim N, Oh HH, Myung DS, Kim JS, Cho SB, Lee WS, Kim HS, Ahn BW, Joo YE. Rice prolamin extract ameliorates acute murine colitis by inhibiting nuclear factor‐kappa B and modulating intestinal apoptosis and cell proliferation. Clin Exp Immunol, 2014;178(3):537–47
   PubMed Web of Science ®Google Scholar
• Dieleman LA, Palmen MJ, Akol H, Bloemena E, Peña AS, Meuwissen SG, Van Rees EP. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol, 1998;114(3):385–91
   PubMed Web of Science ®Google Scholar
• Diwan M, Dawar H, Talwar GP. Induction of early and bioeffective antibody response in rodents with the anti-Leutinizing hormone releasing hormone vaccine given as single dose in biodegradable microspheres along with the alum. Prostate, 1998;35:279–84
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Yusta B, Boushey RP, DeForest L, Brubaker PL. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol, 1999;276:79–91
   PubMed Web of Science ®Google Scholar
• Egger B, Procaccino F, Sarosi I, Tolmos J, Büchler MW, Eysselein VE. Keratinocyte growth factor ameliorates dextran sodium sulfate colitis in mice. Dig Dis Sci, 1999;44(4):836–44
   PubMed Web of Science ®Google Scholar
• El-Jamal N, Erdual E, Neunlist M, Koriche D, Dubuquoy C, Maggiotto F, Chevalier J, Berrebi D, Dubuquoy L, Boulanger E, et al. Glugacon-like peptide-2 (GLP-2): Broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration. Am J Physiol Gastrointest Liver Physiol, 2014; pii: ajpgi.00389.2012
   PubMed Web of Science ®Google Scholar
• Feng S, Nie L, Zou P, Suo J. Co-encapsulation of human serum albumin and superparamagnetic iron oxide in PLGA nanoparticles: Part I. Effect of process variables on the mean size. J Microencapsul, 2014;31(2):147–55
   PubMed Web of Science ®Google Scholar
• Frokjaer S, Otzen DE. Protein drug stability: A formulation challenge. Nat Rev, 2005;4:298–306
   Google Scholar
• Ge PL, Li N, Jia QB. Effect of glucagon-like peptide-2 (GLP-2) on intestinal barrier function in bile duct ligated rats. Sichuan Da Xue Xue Bao Yi Xue Ban, 2010;41(3):476–9
   PubMedGoogle Scholar
• Guan L, Gong D, Tian N, Zou Y. Uncoupling protein 2 involved in protection of glucagon-like peptide 2 in small intestine with ischemia-reperfusion injury in mice. Dig Dis Sci, 2005;50:554–60
   PubMed Web of Science ®Google Scholar
• Guan X, Stoll B, Lu X, Tappenden KA, Holst JJ, Hartmann B, Burrin DG. GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets. Gastroenterology, 2003;125:136–47
   PubMed Web of Science ®Google Scholar
• Hayashi Y, Aoyagi K, Morita I, Yamamoto C, Sakisaka S. Oral administration of mesalazine protects against mucosal injury and permeation in dextran sulfate sodium-induced colitis in rats. Scand J Gastroenterol, 2009;44(11):1323–31
   PubMed Web of Science ®Google Scholar
• Heureux MC, Brubaker PL. Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis. J Pharmacol Exp Ther, 2003;306:347–354
   PubMed Web of Science ®Google Scholar
• Housley RM, Morris CF, Boyle W, Ring B, Biltz R, Tarpley JE, Aukerman SL, Devine PL, Whitehead RH, Pierce GF. Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract. J Clin Invest, 1994;94:1764–77
   PubMed Web of Science ®Google Scholar
• Hsieh J, Longuet C, Maida A, Bahrami J, Xu E, Baker CL, Brubaker1 PL, Drucker DJ, Adeli K. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology, 2009;137:997–1005
   PubMed Web of Science ®Google Scholar
• Jaklenec A, Hinckfuss A, Bilgen B, Ciombor DM, Aaron R, Mathiowitz E. Sequential release of bioactive IGF-I and TGF-beta 1 from PLGA microsphere-based scaffolds. Biomaterials, 2008;29(10):1518–25
   PubMed Web of Science ®Google Scholar
• Jiang G, Thanoo BC, DeLuca PP. Effect of osmotic pressure in the solvent extraction phase on BSA release profile from PLGA microspheres. Pharm Dev Technol, 2002;7(4):391–9
   PubMed Web of Science ®Google Scholar
• Kaji T, Tanaka H, Redstone H, Wallace L, Holst JJ, Sigalet DL. Temporal changes in the intestinal growth promoting effects of glucagon-like peptide 2 following intestinal resection. J Surg Res, 2009;152:271–80
   PubMed Web of Science ®Google Scholar
• Li JY, YU Y, Hao J, Jin Y, Xu HJ. Determination of diamine oxidase activity in intestinal tissue and blood using spectrophotometry. Amino Acids Biotic Resour, 1996;18(4):28–30
   Google Scholar
• Madsen KB, Askov-Hansen C, Naimi RM, Brandt CF, Hartmann B, Holst JJ, Mortensen PB, Jeppesen PB. Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1 + GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study. Regul Pept, 2013;184(2):30–9
   PubMed Web of Science ®Google Scholar
• Martin GR, Wallace LE, Sigalet DL. Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. Am J Physiol Gastrointest Liver Physiol, 2004;286:964–72
   PubMed Web of Science ®Google Scholar
• Mathew A, Fukuda T, Nagaoka Y, Hasumura T, Morimoto H, Yoshida Y, Maekawa T, Venugopal K, Kumar DS. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease. PLoS One, 2012;7(3):e32616
   PubMed Web of Science ®Google Scholar
• Moran GW, O'Neill C, McLaughlin JT. GLP-2 enhances barrier formation and attenuates TNFα-induced changes in a Caco-2 cell model of the intestinal barrier. Regul Pept, 2012;178(1–3):95–101
   PubMed Web of Science ®Google Scholar
• Morita T, Sakamura Y, Horikiri Y, Suzuki T, Yoshino H. Protein encapsulation into biodegradable microspheres by a novel S/O/W emulsion method using poly(ethylene glycol) as a protein micronization adjuvant. J Control Realease, 2000;69(3):435–44
   PubMed Web of Science ®Google Scholar
• Ørskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept, 2005;124:105–12
   PubMed Web of Science ®Google Scholar
• Pedersen NB, Hjollund KR, Johnsen AH, Orskov C, Rosenkilde MM, Hartmann B, Holst JJ. Porcine glucagon-like peptide-2: Structure, signaling, metabolism and effects. Regul Pept, 2008;146:310–20
   PubMed Web of Science ®Google Scholar
• Petersen YM, Hartmann B, Holst JJ, Huerou-Luron I, Bjørnvad CR, Sangild PT. Introduction of enteral food increases plasma GLP-2 and decreases GLP-2 receptor mRNA abundance during pig development. J Nutr June, 2003;133(6):1781–6
   PubMed Web of Science ®Google Scholar
• Pinholt C, Kapp SJ, Bukrinsky JT, Hostrup S, Frokjaer S, Norde W, Jorgensen L. Influence of acylation on the adsorption of GLP-2 to hydrophobic surfaces. Int J Pharm, 2013;440(1):63–71
   PubMed Web of Science ®Google Scholar
• Poritz LS, Garver KI, Green C, Fitzpatrick L, Ruggiero F, Koltun WA. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. J Surg Res, 2007;140(1):12–19
   PubMed Web of Science ®Google Scholar
• Qi KK, Wu J, Wan J, Men XM, Xu ZX. Purified PEGylated porcine glucagon-like peptide-2 reduces the severity of colonic injury in a murine model of experimental colitis. Peptide, 2014;52:11–18
   PubMed Web of Science ®Google Scholar
• Setia S, Nehru B, Sanyal SN. Celecoxib prevents colitis associated colon carcinogenesis: An upregulation of apoptosis. Pharmacol Rep Pr, 2014;66:1083–91
   PubMed Web of Science ®Google Scholar
• Sigalet DL, de Heuvel E, Wallace L, Bulloch E, Turner J, Wales PW, Nation P, Wizzard PR, Hartmann B, Assad M, Holst JJ. Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs. Regul Pept, 2014;188:70–80
   PubMed Web of Science ®Google Scholar
• Sigalet DL, Wallace LE, Holst JJ, Martin GR, Kaji T, Tanaka H, Sharkey KA. Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol, 2007;293(1):211–21
   PubMed Web of Science ®Google Scholar
• Stephens J, Stoll B, Cottrell J, Chang X, Helmrath M, Burrin DG. Glucagon-like peptide-2 acutely increases proximal small intestinal blood flow in TPN-fed neonatal piglets. Am J Physiol Regul Integr Comp Physiol, 2006;290(2):283–9
   PubMed Web of Science ®Google Scholar
• Tavares W, Drucker DJ, Brubaker PL. Enzymatic-and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. Am J Physiol Endocrinol Metab, 2000;278:134–9
   PubMed Web of Science ®Google Scholar
• Thymann T, Le Huërou-Luron I, Petersen YM, Hedemann MS, Elinf J, Jensen BB, Holst JJ, Hartmann B, Sangild PT. Glucagon-like peptide 2 treatment may improve intestinal adaptation during weaning. J Anim Sci, 2014;92(5):2070–9
   PubMed Web of Science ®Google Scholar
• Tsai CH, Hill M, Asa SL, Brubaker PL, Drucker DJ. Intestinal growth promoting properties of glucagon-like peptide-2 in mice. Am J Physiol, 1997;273:77–84
   PubMed Web of Science ®Google Scholar
• Vegge A, Thymann T, Lund P, Stoll B, Bering SB, Hartmann B, Jelsing J, Qvist N, Burrin DG, Jeppesen PB, et al. Glucagon-like peptide-2 induces rapid digestive adaptation following intestinal resection in preterm neonates. Am J Physiol Gastrointest Liver Physiol, 2013;305(4):G277–85
   PubMed Web of Science ®Google Scholar
• Vetuschi A, Latella G, Sferra R, Caprilli R, Gaudio E. Increased proliferation and apoptosis of colonic epithelial cells in dextran sulfate sodium induced colitis in rats. Dig Dis Sci, 2002;47:1447–57
   PubMed Web of Science ®Google Scholar
• Visscher GE, Robison RL, Maulding HV, Fong JW, Pearson JE, Argentieri GJ. Biodegradation of and tissue reaction to 50–50 poly (dl-lactide-co-glycolide) microcapsules. J Biomed Mater Res, 1985;19(3):349–65
   PubMed Web of Science ®Google Scholar
• Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm, 2005;289:1–30
   PubMed Web of Science ®Google Scholar
• Wang S, Qiu Y, Zhu Z, Ma Z, Xia C, Zhu F. Histomorphological study of the spinal growth plates from the convex side and the concave side in adolescent idiopathic scoliosis. J Orthop Surg Res, 2007;11(2):19
   Google Scholar
• Washizawa N, Gu LH, Gu L, Openo KP, Jones DP, Ziegler TR. Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats. J Parenter Enteral Nutr, 2004;28:399–409
   PubMed Web of Science ®Google Scholar
• Xie S, Liu B, Fu S, Wang W, Yin Y, Li N, Chen W, Liu J, Liu D. GLP-2 suppresses LPS-induced inflammation in macrophages by inhibiting ERK phosphorylation and NF-κB activation. Cell Physiol Biochem, 2014;34(2):590–602
   PubMed Web of Science ®Google Scholar
• Yin D, Lu Y, Zhang H, Zhang G, Zou H, Sun D, Zhong Y. Preparation of glucagon-like peptide-1 loaded PLGA microspheres: Characterizations, release studies and bioactivities in vitro/in vivo. Chem Pharm Bull, 2008;56(2):156–61
   PubMed Web of Science ®Google Scholar
• Yin DF, Wu C, Lu Y, Yang L, Zhong YQ. Studies on the preparation and release in vitro of the glucagon-like peptide-1 loaded long-acting injectable microspheres. Pharm Care Res, 2005;5(3):243–7
   Google Scholar
• Yukitake H, Kimura H, Suzuki H, Tajima Y, Sato Y, Imaeda T, Kajino M, Takizawa M. BTZO-15, an ARE-Activator, Ameliorates DSS-and TNBS-induced Colitis in rats. PLoS One, 2011;6(8):e23256
   PubMed Web of Science ®Google Scholar
• Yusta B, Huang L, Munroe D, Wolff G, Fantaske R, Sharma S, Demchyshyn L, Asa SL, Drucker DJ. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology, 2000;119:744–55
   PubMed Web of Science ®Google Scholar